Q-omics provides the consensus-scored FUZ profile across patient tissues and cancer cell-line models. FUZ expression is associated with patient survival in 24 of 34 cancer types, with the highest sampling consensus in BRCA. Among the 18 cancer types available for tumor–normal comparison, FUZ is differentially expressed in 10, with the highest sampling consensus in KICH. Additionally, FUZ RNA expression shows 17,578 significant gene co-expression associations, with the highest sampling consensus in ACC. Together, these results highlight BRCA, KICH, and ACC as cancer lineages where FUZ shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for FUZ — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes FUZ survival associations across molecular data types. FUZ RNA expression shows survival associations in the most cancer types (24), followed by mutation status (3) and mass-spec protein abundance (4). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible FUZ RNA expression–survival associations across cancer types. High FUZ expression shows unfavorable associations in STAD and LGG, but favorable associations in BRCA, HNSC, KIRC and KIRP. The BRCA Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify BRCA as the clearest survival context for FUZ RNA expression.
This table summarizes FUZ tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 10, while mass-spec protein shows differences in 3. The strongest signals are observed in KICH for RNA and LUAD for protein.
This table ranks reproducible tumor–normal expression differences for FUZ. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. FUZ shows lower tumor expression in KICH, LUAD, HNSC and UCEC and higher tumor expression in CHOL and KIRC. The KICH box plot shows higher FUZ RNA expression in normal versus tumor tissue (log2 FC = −1.373, t-test p < 0.001).
This table shows molecular features associated with FUZ in patient tissues and cancer cell lines. In patient samples, FUZ shows the broadest associations at the RNA and protein expression levels, with ACC recurring as the lineage with the largest associated feature set. In cancer cell lines, FUZ RNA and mutation anchors are most strongly linked to RNA-expression features, especially in KIDNEY, while CRISPR and shRNA rows add functional-dependency signals in BONE and BLOOD_Leukemia.
